Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

Cancer Chemotherapy and Pharmacology

Volumn 36, Issue 5, 1995, Pages 393-403

  Houghton, Peter J ^a   Cheshire, Pamela J ^a   Hallman II, James D ^a   Lutz, Lois ^a   Friedman, Henry S ^b   Danks, Mary K ^a   Houghton, Janet A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Camptothecin; CPT 11; Irinotecan; Topoisomerases; Topotecan; Xenografts

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; MELPHALAN; TOPOTECAN; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER GRAFT; CANCER GROWTH; CANCER REGRESSION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

ADENOCARCINOMA; ANIMAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMAN; MICE; MICE, INBRED CBA; NEOPLASMS, EXPERIMENTAL; RANDOM ALLOCATION; RHABDOMYOSARCOMA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029116438     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00686188     Document Type: Article

References (44)

1. DNA topoisomerases
2. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity
3. Treatment of malignant melanoma with camptothecin (NSC-100880)
4. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880)
5. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
6. DNA topoisomerase 1-targeted chemotherapy of human colon cancer xenografts
7. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins
8. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors
9. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts
10. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors
11. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice
12. Preclinical evaluation of CPT-11, a camptothecin derivative
13. Experimental activity of CPT-11 in vitro and in vivo
14. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
15. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydoxycamptothecin
16. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo
17. Phase I clinical study of CPT-11
18. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
19. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma
20. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
21. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
22. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer
23. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer
24. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer
25. Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer
26. Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma
27. Growth and characterization of childhood rhabdomyosarcomas as xenografts
28. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins
29. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma
30. A specific chromosomal abnormality in rhabdomyosarcoma
31. Childhood rhabdomyosarcoma xenografts: response to DNA interacting agents and agents used in current clinical therapy
32. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma
33. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard
34. Growth characteristics of human colorectal tumors during serial passage in immune-deprived mice
35. Maintenance of biological and biochemical characteristics of human colorectal tumors during serial passage in immune-deprived mice
36. The suitability and use of human tumor xenografts
37. On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice
38. Drug sensitivity and resistance in the xenograft model
39. Experimental chemotherapy of human medulloblastom cell lines and transplantable xenografts with bifunctional alkylating agents
40. The s-phase cytotoxicity of comptothecin
41. Irinotecan (CPT-11) high dose escalation with intensive high-dose loperamide to control diarrhea
42. Metabolic fate of irinotecan in humans: correlation of glucoronidation with diarrhea
43. Enhanced acetominophen toxicity in rats with bilirubin glucoronyl transferase deficiency
44. Hepatic UDP-glucoronic acid regulation during acetominophen biotransformation in rats